潜在的医疗保险储蓄来自 ACE 抑制剂和血管紧张素 II 受体阻滞剂的仿制药替代和治疗性互换。
Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers.
机构信息
Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Harvard Medical School Multi-Campus Geriatric Fellowship, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
出版信息
JAMA Intern Med. 2019 Dec 1;179(12):1712-1714. doi: 10.1001/jamainternmed.2019.3107.
Abstract
This economic evaluation study estimates the potential Medicare savings from generic substitution and therapeutic interchange of brand-name hypertension medications.
摘要
本经济评估研究旨在估算通过仿制药替代和品牌高血压药物的治疗转换，潜在的医疗保险储蓄。
相似文献
1
Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers.潜在的医疗保险储蓄来自 ACE 抑制剂和血管紧张素 II 受体阻滞剂的仿制药替代和治疗性互换。
JAMA Intern Med. 2019 Dec 1;179(12):1712-1714. doi: 10.1001/jamainternmed.2019.3107.
2
Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.三种通用型血管紧张素II受体阻滞剂商业化对加拿大魁北克不良事件的影响：基于人群的时间序列分析
Circ Cardiovasc Qual Outcomes. 2017 Oct;10(10). doi: 10.1161/CIRCOUTCOMES.117.003891.
3
[Health care too costly? Saving more than 10 million euros in 2 months!].[医疗保健费用太高？两个月节省超过1000万欧元！]
MMW Fortschr Med. 2003 Nov 20;145(47):65.
4
Clinical and economic implications of therapeutic switching of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors: a population-based study.血管紧张素受体阻滞剂转换为血管紧张素转换酶抑制剂的治疗转换的临床和经济意义：一项基于人群的研究。
J Hypertens. 2019 Jun;37(6):1285-1293. doi: 10.1097/HJH.0000000000002009.
5
Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review.抗高血压药物的成本效益分析：系统评价。
Am J Prev Med. 2017 Dec;53(6S2):S131-S142. doi: 10.1016/j.amepre.2017.06.020.
6
[Therapy of hypertension. Cost conscious prevention of complications].[高血压治疗。注重成本的并发症预防]
MMW Fortschr Med. 2003 Nov 20;145(47):64.
7
[Added organ protection at little cost. Double savings with ACE inhibitors].[以低成本增加器官保护。ACE抑制剂带来双重获益]
MMW Fortschr Med. 2003 Nov 27;145(48):63.
8
Assessing step-therapy programs:a step in the right direction.评估逐步治疗方案：朝着正确方向迈出的一步。
J Manag Care Pharm. 2007 Apr;13(3):273-5. doi: 10.18553/jmcp.2007.13.3.273.
9
[Do generic drugs help control expenditure on hypertension? Apropos of a case].[仿制药有助于控制高血压治疗费用吗？基于一个案例]
Gac Sanit. 2004 Mar-Apr;18(2):137-44. doi: 10.1016/s0213-9111(04)71819-1.
10
[Generic drugs and the consumption trends of antihypertensives in Morocco].[摩洛哥的仿制药与抗高血压药物消费趋势]
Therapie. 2013 Sep-Oct;68(5):303-12. doi: 10.2515/therapie/2013048. Epub 2013 Nov 14.
引用本文的文献
1
Testing the unintended cost effects of health policies for generic substitutions: the case of China's National Volume-Based Procurement (NVBP) policy.测试仿制药替代健康政策的意外成本影响：以中国国家集中带量采购（NVBP）政策为例。
Health Policy Plan. 2025 Feb 6;40(2):194-205. doi: 10.1093/heapol/czae101.
2
Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions.评估州政府对仿制药和可互换生物替代品的监管差异。
JAMA Intern Med. 2021 Jan 1;181(1):16-22. doi: 10.1001/jamainternmed.2020.3588.
Zotero 插件